Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Marathon Asset Management Ltd

Marathon Asset Management Ltd increased its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 2.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 762,151 shares of the biopharmaceutical company's stock after purchasing an additional 18,424 shares during the period. Marathon Asset Management Ltd owned approximately 0.13% of Royalty Pharma worth $21,561,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Swedbank AB boosted its stake in shares of Royalty Pharma by 2.0% during the 3rd quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company's stock worth $311,964,000 after purchasing an additional 213,900 shares during the period. New South Capital Management Inc. raised its stake in shares of Royalty Pharma by 60.7% during the second quarter. New South Capital Management Inc. now owns 2,348,977 shares of the biopharmaceutical company's stock valued at $61,943,000 after acquiring an additional 887,522 shares in the last quarter. Homestead Advisers Corp boosted its holdings in shares of Royalty Pharma by 40.7% in the first quarter. Homestead Advisers Corp now owns 1,892,540 shares of the biopharmaceutical company's stock valued at $57,502,000 after purchasing an additional 547,000 shares during the period. Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of Royalty Pharma by 10.4% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 1,856,998 shares of the biopharmaceutical company's stock valued at $56,396,000 after purchasing an additional 175,261 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Royalty Pharma by 6.0% in the second quarter. Bank of New York Mellon Corp now owns 1,533,094 shares of the biopharmaceutical company's stock valued at $40,428,000 after purchasing an additional 86,248 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Down 0.2 %

Royalty Pharma stock traded down $0.07 during mid-day trading on Friday, reaching $27.98. 1,177,560 shares of the company were exchanged, compared to its average volume of 2,605,586. The business has a fifty day moving average of $27.95 and a 200 day moving average of $27.70. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. The firm has a market cap of $16.61 billion, a P/E ratio of 24.82, a PEG ratio of 4.10 and a beta of 0.46. Royalty Pharma plc has a 12-month low of $25.20 and a 12-month high of $31.66.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping analysts' consensus estimates of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The company had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.83 million. During the same quarter in the prior year, the business earned $0.85 earnings per share. Research analysts anticipate that Royalty Pharma plc will post 4.05 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $0.21 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.00%. Royalty Pharma's payout ratio is 74.34%.

Analyst Upgrades and Downgrades

RPRX has been the subject of a number of research reports. The Goldman Sachs Group boosted their price target on Royalty Pharma from $50.00 to $51.00 and gave the company a "buy" rating in a report on Wednesday, August 14th. StockNews.com upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a report on Tuesday, September 17th. Finally, Morgan Stanley boosted their price target on Royalty Pharma from $48.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, July 11th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.